JP2025508660A - ２－ヒドロキシプロピル－β－シクロデキストリンによる高トリグリセリド血症の治療 - Google Patents

２－ヒドロキシプロピル－β－シクロデキストリンによる高トリグリセリド血症の治療 Download PDF

Info

Publication number
JP2025508660A
JP2025508660A JP2024543311A JP2024543311A JP2025508660A JP 2025508660 A JP2025508660 A JP 2025508660A JP 2024543311 A JP2024543311 A JP 2024543311A JP 2024543311 A JP2024543311 A JP 2024543311A JP 2025508660 A JP2025508660 A JP 2025508660A
Authority
JP
Japan
Prior art keywords
amount
subject
administration
cyclodextrin
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024543311A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508660A5 (https=
Inventor
カム，ジェイソン
Original Assignee
ベレン セラピューティクス ピー．ビー．シー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベレン セラピューティクス ピー．ビー．シー． filed Critical ベレン セラピューティクス ピー．ビー．シー．
Publication of JP2025508660A publication Critical patent/JP2025508660A/ja
Publication of JP2025508660A5 publication Critical patent/JP2025508660A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2024543311A 2022-02-18 2023-02-17 ２－ヒドロキシプロピル－β－シクロデキストリンによる高トリグリセリド血症の治療 Pending JP2025508660A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263311536P 2022-02-18 2022-02-18
US63/311,536 2022-02-18
PCT/IB2023/051467 WO2023156970A1 (en) 2022-02-18 2023-02-17 Treatment of hypertriglyceridemia with 2-hydroxypropyl-beta-cyclodextrin

Publications (2)

Publication Number Publication Date
JP2025508660A true JP2025508660A (ja) 2025-04-10
JP2025508660A5 JP2025508660A5 (https=) 2026-02-24

Family

ID=85476260

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024543311A Pending JP2025508660A (ja) 2022-02-18 2023-02-17 ２－ヒドロキシプロピル－β－シクロデキストリンによる高トリグリセリド血症の治療

Country Status (11)

Country Link
US (1) US20240398849A1 (https=)
EP (1) EP4479064A1 (https=)
JP (1) JP2025508660A (https=)
KR (1) KR20240148426A (https=)
CN (1) CN118715017A (https=)
AU (1) AU2023222567A1 (https=)
CA (1) CA3244447A1 (https=)
IL (1) IL315046A (https=)
MX (1) MX2024010110A (https=)
TW (1) TW202342072A (https=)
WO (1) WO2023156970A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003063824A2 (en) * 2002-02-01 2003-08-07 Shimoda Biotech (Pty) Ltd Pharmaceutical composition
CN1745746A (zh) * 2004-09-09 2006-03-15 天津药物研究院 冰片的羟丙基－β－环糊精包合物及其制剂和制备方法
CN1961892A (zh) * 2005-11-08 2007-05-16 天津药物研究院 降香羟丙基－β－环糊精包合物及其制剂和制备方法
GB0710439D0 (en) * 2007-05-31 2007-07-11 Uni I Oslo Oral dosage form
US8975241B2 (en) * 2009-10-08 2015-03-10 Song Ho Biomed Co., Ltd. Composition for treating and preventing obesity including high water-soluble 2-hydroxypropyl-betacyclodextrin as effective component
FR3014694B1 (fr) * 2013-12-13 2016-11-11 Roquette Freres Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl

Also Published As

Publication number Publication date
MX2024010110A (es) 2024-08-30
AU2023222567A1 (en) 2024-09-19
US20240398849A1 (en) 2024-12-05
CA3244447A1 (en) 2023-08-24
CN118715017A (zh) 2024-09-27
EP4479064A1 (en) 2024-12-25
WO2023156970A1 (en) 2023-08-24
IL315046A (en) 2024-10-01
KR20240148426A (ko) 2024-10-11
TW202342072A (zh) 2023-11-01

Similar Documents

Publication Publication Date Title
KR20130026504A (ko) 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법
JP7835735B2 (ja) シクロデキストリンによるコレステロール結晶塞栓症の治療方法
Suk et al. Stress-induced cardiomyopathy following cephalosporin-induced anaphylactic shock during general anesthesia
US20240082242A1 (en) Combination therapies
JP2025508660A (ja) ２－ヒドロキシプロピル－β－シクロデキストリンによる高トリグリセリド血症の治療
US20230091966A1 (en) Methods for the treatment of cardiovascular disease with cyclodextrins
US20230375576A1 (en) Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins
CN104507478A (zh) 用于治疗急性冠状动脉综合征的烟酰胺衍生物
US20230302042A1 (en) Methods for the prevention of cholesterol crystal embolization with cyclodextrins
US8252281B2 (en) Methods for the treatment of sepsis and sepsis-associated cardiac dysfunction
JP2014208713A (ja) 冠動脈の描出能改善剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260213